Weyer Christian 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Jan 27, 2020
Insider Transaction Report
Form 4
Weyer Christian
EVP Research and Development
Transactions
- Award
Option to Purchase Common Stock
2020-01-23+7,900→ 7,900 totalExercise: $99.66Exp: 2030-01-23→ Common Stock (7,900 underlying) - Award
Common Stock
2020-01-23+4,800→ 18,560 total - Sale
Common Stock
2020-01-27$94.04/sh−723$67,991→ 17,837 total
Footnotes (3)
- [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
- [F2]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F3]The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.